-
Ahn SH, Park YK, Park ES, Kim JH, Kim DH, Lim KH, Jang MS, Choe WH, Ko SY, Sung IK, Kwon SY, Kim KH, 2014: The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene[J]. J Virol, 88, 6518-6805.
-
Busso ME, Resnick L, Yang BH, Mian AM, 1990: Cellular pharmacology and anti-HIV activity of 2¤, 3¤-dideoxyguanosine[J]. AIDS Res Hum Retrovir, 6, 1139-1146. doi: 10.1089/aid.1990.6.1139
-
Campagna MR, Liu F, Mao R, Mills C, Cai D, Guo F, Zhao X, Ye H, Cuconati A, Guo H, Chang J, Xu X, Block TM, Guo JT, 2013: Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids[J]. J Virol, 87, 6931-6942. doi: 10.1128/JVI.00582-13
-
Chen ZY, Cheng AC, Wang MS, Xu DW, Zeng W, Li Z, 2007: Antiviral effects of PNA in duck hepatitis B virus infection model[J]. Acta Pharmacol Sin, 28, 1652-1658. doi: 10.1111/aphs.2007.28.issue-10
-
Chinese Society of Hepatology and Chinese Society of Infectious Diseases , 2011: Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version)[J]. Zhonghua Liuxing Bingxue Zazhi, 32, 405-415.
-
Christian T, Henry LYC, Anna L, 2014: Hepatitis B virus infection[J]. Lancet, 384, 2053-2063. doi: 10.1016/S0140-6736(14)60220-8
-
Condreav LD, Aldrich CE, Coates L, Mason WS, Wu TT, 1990: Efficient duck hepatitis B virus production by an avian liver tumor cell line[J]. J Virol, 64, 3249-3258.
-
European Association for The Study of The Liver , 2012: EASL clinical practice guidelines: management of chronic hepatitis B virus infection[J]. J Hepatol, 57, 167-185. doi: 10.1016/j.jhep.2012.02.010
-
Guo H, Jiang D, Zhou T, Cuconati A, Block TM, Guo JT, 2007: Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation[J]. J Virol, 81, 12472-12484. doi: 10.1128/JVI.01123-07
-
Guo JT, Pryce M, Wang X, Barrasa MI, Hu J, Seeger C, 2013: Conditional replication of duck hepatitis B virus in hepatoma cells[J]. J Virol, 77, 1885-1893.
-
Guo XH, Wu JS, Wei FL, Ouyang YB, Li Q, Liu K, Wang YJ, Zhang YL, Chen DX (2018) Trends in hepatitis B virus resistance to nucleoside/nucleotide analogs in North China from 2009 to 2016: a retrospective study. Int J Antimicrob Agents. https: //doi.org/10.1016/j.ijantimicag.2018.04.002
-
Jacquard AC, Brunelle MN, Pichoud C, Durantel D, Carrouée-Durantel S, Trepo C, Zoulim F, 2006: In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2¤, 3¤-dideoxy-3¤-fluoroguanosine[J]. Antimicrob Agents Chemother, 50, 955-961. doi: 10.1128/AAC.50.3.955-961.2006
-
Jeffrey DM, Raymond FS, John WM, Nicolas SC, 2014: Molecular mechanism of HIV-1 resistance to 3¤-azido-2¤3¤-dideoxyguanosine[J]. Antiviral Res, 101, 62-67. doi: 10.1016/j.antiviral.2013.10.017
-
Jones SA, Murakami E, Delaney W, Furman P, Hu J, 2013: Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine[J]. Antimicrob Agents Chemother, 57, 4181-4189. doi: 10.1128/AAC.00599-13
-
Korba BE, Cote P, Hornbuckle W, Tennant BC, Gerin JL, 2000: Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans[J]. Hepatology, 31, 1165-1175. doi: 10.1053/he.2000.5982
-
Ladner SX, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeqer C, King RW, 1997: Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication[J]. Antimicrob Agents Chemother, 41, 1715-1720. doi: 10.1128/AAC.41.8.1715
-
Li Z, Huang X, Jiang Z, Xiao Y, Liu C, Zhang L, Shu B, Huang J, Li T, Wang T, Wang F, 2008: A sensitive and specific liquid chromatography-mass spectrometry method for determination of metacavir in rat plasma[J]. J Chromatogr B, 864, 9-14. doi: 10.1016/j.jchromb.2007.12.022
-
Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M, 2012: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update[J]. Hepatol Int, 6, 531-561. doi: 10.1007/s12072-012-9365-4
-
Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, Li S, Li W, Block TM, Chang J, Guo JT, 2013: Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes[J]. PLoS Pathog, 9, e1003613-. doi: 10.1371/journal.ppat.1003613
-
Meng T, Shi XF, Gong XY, Deng HJ, Huang Y, Shan XF, Shan YL, Huang AL, Long QX, 2017: Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014)[J]. J Global Antimicrob Resist, 8, 74-81. doi: 10.1016/j.jgar.2016.10.012
-
Menne S, Cote PJ, 2007: The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection[J]. World J Gastroenterol, 13, 104-124. doi: 10.3748/wjg.v13.i1.104
-
Menne S, Butler SD, George AL, Tochkov IA, Zhu Y, Xiong S, Gerin JL, Cote PJ, Tennant BC, 2008: Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection[J]. Antimicrob Agents Chemother, 52, 3617-3632.
-
Schinazi RF, Bassit L, Clayton MM, Sun B, Kohler JJ, Obikhod A, Arzumanyan A, Feitelson MA, Barbara R, Antonio B, 2012: Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication[J]. Antimicrob Agents Chemother, 56, 6186-6191. doi: 10.1128/AAC.01483-12
-
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ, 2015: Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013[J]. Lancet, 386, 1546-1555. doi: 10.1016/S0140-6736(15)61412-X
-
Staschke KA, Colacino JM, 1994: Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5¤-triphosphate of fialuridine[J]. J Virol, 68, 8265-8269.
-
Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Suzuki Y, Kumada H, 2014: Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir[J]. Drug Des Devel Ther, 8, 869-873.
-
Wang J, Shen T, Huang XB, Renuka Kumar G, Chen XM, Zeng ZZ, Zhang RY, Chen R, Tong Li, Zhang T, Yuan Q, Li PC, Huang Q, Colonno R, Jia JD, Hou JL, McCrae MA, Gao ZL, Ren H, Xia NS, Zhuang H, Lu FM, 2016: Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 65, 700-710. doi: 10.1016/j.jhep.2016.05.029
-
Watcharasak C, Carolyn P, Fausta AD, Diane G, Anna SFLK, 2011: Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B[J]. J Hepatol, 54, 12-18. doi: 10.1016/j.jhep.2010.06.016
-
Yu W, Goddard C, Clearfield E, Mills C, Xiao T, Guo H, Morrey JD, Motter NE, Zhao K, Block TM, Cuconati A, Xu X, 2011: Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion[J]. J Med Chem, 54, 5660-5670. doi: 10.1021/jm200696v
-
Zeng W, Cheng AC, Chen ZL, Luo QH, Sun YB, Li Z, Bi FJ, 2009: In vivo assessment of mitochondrial toxicity of PNA in Rhesus monkeys after three months of intravenous administration[J]. Acta Pharmacol Sin, 30, 1666-1673. doi: 10.1038/aps.2009.163
-
Zhang P, Zhang L, Jiang Z, Wang T, Chen H, Xiong Y, Li Z, 2010: In vitro mitochondrial toxicity of PNA, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus[J]. Antimicrob Agents Chemother, 54, 4887-4892. doi: 10.1128/AAC.00794-10
-
Zhang P, Zhang L, Jiang Z, Xiong Y, Chen H, Tao Y, Hu M, Li Z, 2011: Evaluation of mitochondrial toxicity in Marmota himalayana treated with PNA, a novel 2¤, 3¤-dideoxyguanosine prodrug for treatment of hepatitis B virus[J]. Antimicrob Agents Chemother, 55, 1930-1936. doi: 10.1128/AAC.01520-10
-
Zhang P, Liu F, Guo F, Zhao Q, Chang J, Guo JT, 2016: Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors[J]. Antivir Res, 131, 40-48. doi: 10.1016/j.antiviral.2016.04.007
-
Zhang HY, Liu LG, Ye CY, Chen CH, Hang SX, Zhu Z, Shen HY, Huang ZY, Chen WY, Xue Y, 2018: Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016)[J]. Virus Genes, 54, 41-47. doi: 10.1007/s11262-017-1518-z
-
Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K, 2009: Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues[J]. Antivir Chem Chemother, 19, 165-176. doi: 10.1177/095632020901900404
-
Zoulim F, Locarnini S, 2009: Hepatitis B virus resistance to nucleo(t)ide analogues[J]. Gastroenterology, 137, 1593-1608. doi: 10.1053/j.gastro.2009.08.063